Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Universal Ibogaine Inc V.IBO

Alternate Symbol(s):  IBOGF

Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The Company is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. It is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.


TSXV:IBO - Post by User

Universal Ibogaine Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by Pabloparkeron Jun 27, 2022 11:07am
50 Views
Post# 34784566

$IBOGF announced a decisive addition of clinical trials

$IBOGF announced a decisive addition of clinical trials Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities